Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Oct;33(10):1704–1708. doi: 10.1128/aac.33.10.1704

Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites.

K Akahane 1, M Sekiguchi 1, T Une 1, Y Osada 1
PMCID: PMC172741  PMID: 2556076

Abstract

The relationship between the chemical structure and epileptogenic activity of quinolones was investigated. When the quinolones were administered intravenously to mice concomitantly with oral biphenylacetic acid, a major metabolite of the nonsteroidal antiinflammatory drug fenbufen, enoxacin, norfloxacin, ciprofloxacin, and pipemidic acid, which have an unsubstituted piperazine moiety at the 7 position of their parent nuclei, provoked clonic convulsions and subsequent death at doses of 6.25 mg/kg or more in a dose-dependent manner. AM-1091 and T-3262, which have an unsubstituted aminopyrrolidine moiety at their 7 positions, were less epileptogenic than the compounds listed above were. In contrast, ofloxacin, AT-4140, and nalidixic acid, which have piperazine substituted with methyl group(s) or no piperazine moiety at their 7 positions, never induced convulsions, even at doses of 100 mg/kg. Lomefloxacin, which has a 3-methyl piperazine, however, provoked convulsions at doses of 6.25 mg/kg or more. In the presence of biphenylacetic acid, all the test quinolones except nalidixic acid competitively inhibited [3H]muscimol binding to receptor sites for gamma-aminobutyric acid (GABA) in vitro. Nalidixic acid did not inhibit the binding at all, even at the highest concentration tested, i.e., 10(-4) M. The 50% inhibition doses for [3H]muscimol binding varied within 4 orders of magnitude or more, between 10(-8) to more than 10(-4) M for various compounds, and there was a close correlation between the epileptogenic activities of quinolones and their inhibitory potencies for [3H]muscimol binding to GABA receptor sites. These results indicate that the epileptogenic activity of quinolones possibly relates to the GABA-like structures of substituents at their 7 positions, which act as antagonists of GABA receptors.

Full text

PDF
1704

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anastasio G. D., Menscer D., Little J. M., Jr Norfloxacin and seizures. Ann Intern Med. 1988 Jul 15;109(2):169–170. doi: 10.7326/0003-4819-109-2-169. [DOI] [PubMed] [Google Scholar]
  2. Andrews P. R., Johnston G. A. Conformational analysis of muscimol, a GABA agonist. J Theor Biol. 1979 Aug 7;79(3):263–273. doi: 10.1016/0022-5193(79)90345-x. [DOI] [PubMed] [Google Scholar]
  3. Arcieri G., Griffith E., Gruenwaldt G., Heyd A., O'Brien B., Becker N., August R. Ciprofloxacin: an update on clinical experience. Am J Med. 1987 Apr 27;82(4A):381–386. [PubMed] [Google Scholar]
  4. Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):187–193. doi: 10.1093/jac/18.sd.187. [DOI] [PubMed] [Google Scholar]
  5. Davey P. G. Overview of drug interactions with the quinolones. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):97–107. doi: 10.1093/jac/22.supplement_c.97. [DOI] [PubMed] [Google Scholar]
  6. Enna S. J., Snyder S. H. Influences ions, enzymes, and detergents on gamma-aminobutyric acid-receptor binding in synaptic membranes of rat brain. Mol Pharmacol. 1977 May;13(3):442–453. [PubMed] [Google Scholar]
  7. Falch E., Hedegaard A., Nielsen L., Jensen B. R., Hjeds H., Krogsgaard-Larsen P. Comparative stereostructure-activity studies on GABAA and GABAB receptor sites and GABA uptake using rat brain membrane preparations. J Neurochem. 1986 Sep;47(3):898–903. doi: 10.1111/j.1471-4159.1986.tb00695.x. [DOI] [PubMed] [Google Scholar]
  8. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S258–S261. doi: 10.1093/clinids/10.supplement_1.s258. [DOI] [PubMed] [Google Scholar]
  9. Hill D. R., Bowery N. G. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature. 1981 Mar 12;290(5802):149–152. doi: 10.1038/290149a0. [DOI] [PubMed] [Google Scholar]
  10. Ito A., Hirai K., Inoue M., Koga H., Suzue S., Irikura T., Mitsuhashi S. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother. 1980 Feb;17(2):103–108. doi: 10.1128/aac.17.2.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kouno K., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother. 1983 Jul;24(1):78–84. doi: 10.1128/aac.24.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lucet J. C., Tilly H., Lerebours G., Gres J. J., Piguet H. Neurological toxicity related to pefloxacin. J Antimicrob Chemother. 1988 Jun;21(6):811–812. doi: 10.1093/jac/21.6.811. [DOI] [PubMed] [Google Scholar]
  13. Monk J. P., Campoli-Richards D. M. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987 Apr;33(4):346–391. doi: 10.2165/00003495-198733040-00003. [DOI] [PubMed] [Google Scholar]
  14. Olsen R. W. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem. 1981 Jul;37(1):1–13. doi: 10.1111/j.1471-4159.1981.tb05284.x. [DOI] [PubMed] [Google Scholar]
  15. Sato K., Matsuura Y., Inoue M., Une T., Osada Y., Ogawa H., Mitsuhashi S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother. 1982 Oct;22(4):548–553. doi: 10.1128/aac.22.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schousboe A., Thorbek P., Hertz L., Krogsgaard-Larsen P. Effects of GABA analogues of restricted conformation on GABA transport in astrocytes and brain cortex slices and on GABA receptor binding. J Neurochem. 1979 Jul;33(1):181–189. doi: 10.1111/j.1471-4159.1979.tb11720.x. [DOI] [PubMed] [Google Scholar]
  17. Segev S., Rehavi M., Rubinstein E. Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor. Antimicrob Agents Chemother. 1988 Nov;32(11):1624–1626. doi: 10.1128/aac.32.11.1624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Simpson K. J., Brodie M. J. Convulsions related to enoxacin. Lancet. 1985 Jul 20;2(8447):161–161. doi: 10.1016/s0140-6736(85)90270-3. [DOI] [PubMed] [Google Scholar]
  19. Slavich I. L., Gleffe R. F., Haas E. J. Grand mal epileptic seizures during ciprofloxacin therapy. JAMA. 1989 Jan 27;261(4):558–559. [PubMed] [Google Scholar]
  20. Tsuji A., Sato H., Kume Y., Tamai I., Okezaki E., Nagata O., Kato H. Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother. 1988 Feb;32(2):190–194. doi: 10.1128/aac.32.2.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zukin S. R., Young A. B., Snyder S. H. Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc Natl Acad Sci U S A. 1974 Dec;71(12):4802–4807. doi: 10.1073/pnas.71.12.4802. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES